Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Peter Norman. (2014) Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 – 2013. Expert Opinion on Therapeutic Patents 24:5, pages 573-595.
Read now
Read now
Xianming Deng, Hwan Geun Choi, Sara J. Buhrlage & Nathanael S. Gray. (2012) Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 – 2011). Expert Opinion on Therapeutic Patents 22:12, pages 1415-1426.
Read now
Read now
Peter Norman. (2012) Evaluation of WO2011134971, chiral 1,6-napthyridine Syk kinase inhibitors. Expert Opinion on Therapeutic Patents 22:3, pages 335-339.
Read now
Read now
Dimitar G Efremov & Luca Laurenti. (2011) The Syk kinase as a therapeutic target in leukemia and lymphoma. Expert Opinion on Investigational Drugs 20:5, pages 623-636.
Read now
Read now
Articles from other publishers (15)
Rakesh Sahu, Kamal Shah, Yash Gautam & Kaushilya Sahu. (2023) Pyrazine Moiety: Recent Developments in Cancer Treatment. Current Organic Chemistry 27:10, pages 821-843.
Crossref
Crossref
Cheng Wang, Xin Wang, Yao Li, Tianqi Wang, Zhi Huang, Zhongxiang Qin, Shengyong Yang, Rong Xiang & Yan Fan. (2020) Design and optimization of orally spleen tyrosine kinase (SYK) inhibitors for treatment of solid tumor. Bioorganic Chemistry 95, pages 103547.
Crossref
Crossref
Larry Yet. 2018. Privileged Structures in Drug Discovery. Privileged Structures in Drug Discovery
237
283
.
Neil S. Garton, Michael D. Barker, Rob P. Davis, Clement Douault, Edward Hooper-Greenhill, Emma Jones, Huw D. Lewis, John Liddle, Dave Lugo, Scott McCleary, Alex G.S. Preston, Cesar Ramirez-Molina, Margarete Neu, Tracy J. Shipley, Don O. Somers, Robert J. Watson & David M. Wilson. (2016) Optimisation of a novel series of potent and orally bioavailable azanaphthyridine SYK inhibitors. Bioorganic & Medicinal Chemistry Letters 26:19, pages 4606-4612.
Crossref
Crossref
Frank Lovering, Cristina Aevazelis, Jeanne Chang, Christoph Dehnhardt, Lori Fitz, Seungil Han, Kristin Janz, Julie Lee, Neelu Kaila, Joseph McDonald, William Moore, Alessandro Moretto, Nikolaos Papaioannou, David Richard, Mark S. Ryan, Zhao-Kui Wan & Atli Thorarensen. (2016) Imidazotriazines: Spleen Tyrosine Kinase (Syk) Inhibitors Identified by Free-Energy Perturbation (FEP). ChemMedChem 11:2, pages 217-233.
Crossref
Crossref
Gebhard Thoma, Siem Veenstra, Ross Strang, Joachim Blanz, Eric Vangrevelinghe, Jörg Berghausen, Christian C. Lee & Hans-Günter Zerwes. (2015) Orally bioavailable Syk inhibitors with activity in a rat PK/PD model. Bioorganic & Medicinal Chemistry Letters 25:20, pages 4642-4647.
Crossref
Crossref
Dara Ajay, Rahul P Gangwal & Abhay T Sangamwar. (2015) IPAT: a freely accessible software tool for analyzing multiple patent documents with inbuilt landscape visualizer. Pharmaceutical Patent Analyst 4:5, pages 377-386.
Crossref
Crossref
Gebhard Thoma, Alexander B. Smith, Maurice J. van Eis, Eric Vangrevelinghe, Joachim Blanz, Reiner Aichholz, Amanda Littlewood-Evans, Christian C. Lee, Hong Liu & Hans-Günter Zerwes. (2015) Discovery and Profiling of a Selective and Efficacious Syk Inhibitor. Journal of Medicinal Chemistry 58:4, pages 1950-1963.
Crossref
Crossref
Matthew C Lucas & Seng-Lai Tan. (2014) Small-molecule inhibitors of spleen tyrosine kinase as therapeutic agents for immune disorders: will promise meet expectations?. Future Medicinal Chemistry 6:16, pages 1811-1827.
Crossref
Crossref
Atli Thorarensen & Neelu Kaila. (2014) New spleen tyrosine kinase inhibitors: patent applications published during 2011–2013. Pharmaceutical Patent Analyst 3:5, pages 523-541.
Crossref
Crossref
Gebhard Thoma, Joachim Blanz, Peter Bühlmayer, Peter Drückes, Matthias Kittelmann, Alexander B. Smith, Maurice van Eis, Eric Vangrevelinghe, Hans-Günter Zerwes, Jianwei (John) Che, Xiaohui He, Yunho Jin, Christian C. Lee, Pierre-Yves Michellys, Tetsuo Uno & Hong Liu. (2014) Syk inhibitors with high potency in presence of blood. Bioorganic & Medicinal Chemistry Letters 24:10, pages 2278-2282.
Crossref
Crossref
Patricia Castellanos Penton, Xiaomin Wang, Hajera Amatullah, Josephine Cooper, Krystal Godri, Michelle L. North, Nivedita Khanna, Jeremy A. Scott & Chung-Wai Chow. (2013) Spleen tyrosine kinase inhibition attenuates airway hyperresponsiveness and pollution-induced enhanced airway response in a chronic mouse model of asthma. Journal of Allergy and Clinical Immunology 131:2, pages 512-520.e10.
Crossref
Crossref
Huifen Chen, Bryan K. Chan, Jason Drummond, Anthony A. Estrada, Janet Gunzner-Toste, Xingrong Liu, Yichin Liu, John Moffat, Daniel Shore, Zachary K. Sweeney, Thuy Tran, Shumei Wang, Guiling Zhao, Haitao Zhu & Daniel J. Burdick. (2012) Discovery of Selective LRRK2 Inhibitors Guided by Computational Analysis and Molecular Modeling. Journal of Medicinal Chemistry 55:11, pages 5536-5545.
Crossref
Crossref
Rajinder Singh, Esteban S. Masuda & Donald G. Payan. (2012) Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors. Journal of Medicinal Chemistry 55:8, pages 3614-3643.
Crossref
Crossref
John Liddle, Francis L. Atkinson, Michael D. Barker, Paul S. Carter, Neil R. Curtis, Rob P. Davis, Clement Douault, Marion C. Dickson, Dorothy Elwes, Neil S. Garton, Matthew Gray, Thomas G. Hayhow, Clare I. Hobbs, Emma Jones, Stuart Leach, Karen Leavens, Huw D. Lewis, Scott McCleary, Margarete Neu, Vipulkumar K. Patel, Alex G.S. Preston, Cesar Ramirez-Molina, Tracy J. Shipley, Philip A. Skone, Nick Smithers, Donald O. Somers, Ann L. Walker, Robert J. Watson & Gordon G. Weingarten. (2011) Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor. Bioorganic & Medicinal Chemistry Letters 21:20, pages 6188-6194.
Crossref
Crossref